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Abstract
Background: Designing biologically informative models for assessing the safety of
novel agents, especially for cancer immunotherapy, carries substantial challenges.
The choice of an in vivo system for studies on IgE antibodies represents a major
impediment to their clinical translation, especially with respect to class-specific
immunological functions and safety. Fce receptor expression and structure are dif-
ferent in humans and mice, so that the murine system is not informative when
studying human IgE biology. By contrast, FceRI expression and cellular distribution
in rats mirror that of humans.
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Methods: We are developing MOv18 IgE, a human chimeric antibody recognizing
the tumour-associated antigen folate receptor alpha. We created an immunologically
congruent surrogate rat model likely to recapitulate human IgE-FceR interactions
and engineered a surrogate rat IgE equivalent to MOv18. Employing this model, we
examined in vivo safety and efficacy of antitumour IgE antibodies.
Results: In immunocompetent rats, rodent IgE restricted growth of syngeneic
tumours in the absence of clinical, histopathological or metabolic signs associated
with obvious toxicity. No physiological or immunological evidence of a “cytokine
storm” or allergic response was seen, even at 50 mg/kg weekly doses. IgE treatment
was associated with elevated serum concentrations of TNFa, a mediator previously
linked with IgE-mediated antitumour and antiparasitic functions, alongside evidence
of substantially elevated tumoural immune cell infiltration and immunological path-
way activation in tumour-bearing lungs.
Conclusion: Our findings indicate safety of MOv18 IgE, in conjunction with efficacy
and immune activation, supporting the translation of this therapeutic approach to
the clinical arena.
K E YWORD S
AllergoOncology, cancer, IgE, immunotherapy, rat
1 | INTRODUCTION
Preclinical safety assessments for monoclonal antibodies (mAbs),
especially novel immunomodulatory agents, attracted regulatory
attention following the significant unexpected adverse events
observed with an anti-CD28 super-agonist mAb targeting regulatory
T cells during its first-in-human (FIH) clinical trial in 2006.1,2 Identifi-
cation of a pharmacologically relevant animal species for conducting
safety studies is now incorporated in the European Medicines
Agency guidance on taking novel therapeutics from preclinical stud-
ies into FIH clinical trials.2 Design of biologically and immunologically
relevant models represents an even greater challenge for therapeutic
agents with diverse, often multimodal functional profiles, or for
those representing novel therapeutic classes.
For many therapeutic human IgGs, preclinical evaluation of Fc-
mediated immune functions is often performed in immunocompe-
tent mice, because human IgG Fc interacts with murine FccRs.3 For
the same reason, preclinical safety evaluation of IgGs is conducted
in mice or primates, to study the antibody intended for human
administration. In contrast, mouse models for studies of IgE class-
specific immunological functions and safety, including for cancer
immunotherapy, are not useful in the clinical translation of this class.
Differences between species render the mouse system inadequately
representative of human IgE biology. These include the absence of
human IgE binding to murine FceRs4,5 and differential FceRI struc-
ture (murine FceRI is tetrameric, while human FceRI exists both as a
tetramer and a trimer).4 Murine FceRIs are expressed solely on mast
cells and basophils,4 whereas in rats, similar to humans, expression
is on mast cells, basophils, eosinophils, monocytes and macro-
phages.6,7 These features suggest the rat, rather than the mouse, as
a model immune system better suited to preclinical evaluations of
human IgE.
We previously reported the in vivo efficacy of recombinant chi-
meric (mouse/human) antibody, hMOv18 IgE, specific for the human
tumour-associated antigen folate receptor a (FRa), overexpressed in
solid tumours including ovarian carcinomas. The antitumour activity
of hMOv18 IgE was superior to the equivalent hMOv18 IgG in a
syngeneic rat model, and in two human ovarian carcinoma xenograft
mouse models reconstituted with human immune cells.8-12 In prepa-
ration for a clinical trial of hMOv18 IgE, we hypothesized that an
immunocompetent rat model would provide the most comprehensive
evaluation of safety and efficacy. This model was selected because it
provides i) a species in which the native FceR is expressed on effec-
tor cell populations similar to human cells, ii) an opportunity to study
syngeneic tumours in highly vascularized lungs of immunocompetent
animals, iii) a self-replenishing supply of native effector cells and iv)
a chance to evaluate antibody safety in the presence of antitumour
IgE-mediated responses in tumour-bearing animals.11
Although human exposure to exogenous IgE has been
reported,13 an IgE antibody recognizing a tumour antigen has not,
until now, been introduced as a potential anticancer therapeutic. A
conceivable reservation in contemplating a clinical trial is the per-
ceived risk that intravenous IgE administration may trigger systemic
or organ-specific toxicities, including blood basophil activation and
induction of inflammatory cascades, potentially leading to cytokine
storm or allergic reactions. We previously explored the propensity of
human antitumour IgE to trigger human blood basophil activation
and mast cell degranulation in healthy volunteers’ and cancer
patients’ blood ex vivo. We found no evidence of FceRI-mediated
activation of basophils or mast cell degranulation with hMOv18
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IgE.14 However, the safety of hMOv18 IgE in a physiologically and
immunologically relevant immunocompetent tumour-bearing in vivo
system has not yet been evaluated.
Here, we report the design and implementation of a syngeneic
tumour model in immunocompetent rats to examine IgE safety and
compare antitumour efficacy with that of the equivalent IgG2b. Sur-
rogate rat MOv18 IgE and IgG2b antibodies (rMOv18) were gener-
ated. Treated rats were subjected to clinical, histopathological and
metabolic evaluation. Immune cell recruitment and immune mediator
release were interrogated to provide preclinical insights into this
most appropriate immunocompetent host.
2 | METHODS
See Appendix S1 for details about cell lines, isolation of rat immune
cells from blood, antibody binding to cell surface receptors,
quantitative analysis of gene expression in antibody-treated tumour-
bearing rat lungs, Gene Set Enrichment Analysis and multicytokine
bead immunoassays.
2.1 | Generation of anti-FRa antibodies with human
and rat Fc regions
Chimeric mouse/human antibodies, hMOv18 IgE and IgG1 were pre-
pared as before.8 Chimeric mouse/rat rMOv18 IgE and IgG2b were
designed with rat constant and mouse variable domains specific for
human FRa (Figure 1A). Heavy and light chain region sequences
were cloned into single mammalian expression vectors containing a
hygromycin resistance gene (pVITRO1)15 and transfected into Free-
StyleTM 293-F cells. Selected rMOv18 IgE- and IgG2b-transfected
cells were expanded using an AppliFlex Single-Use Bioreactor (App-
likon Biotechnology) (50L bioreactor wave bag, 25L working vol-
ume).
GRAPHICAL ABSTRACT
To study IgE class-specific functions and safety, we designed a surrogate rat tumour model and rat equivalent antibodies of a human/chimeric
IgE therapeutic candidate recognising a tumour associated antigen. IgE restricted tumour growth, elevated intratumoural immune cell infiltration
and enhanced immune pathway activation, without clinical, histopathological or metabolic toxicity signs, nor immunological evidence of allergic
response or cytokine storm. This model may inform translation of anti-tumour IgE antibodies to clinical study, and help to dissect IgE functions
in AllergoOncology, allergic inflammation, allergen immunotherapy and anti-parasitic responses.
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2.2 | Purification of recombinant anti-FRa
antibodies with human and rat Fc regions
rMOv18 IgE and IgG2b antibodies were purified using MEP (4-mer-
capto-ethyl-pyridine) HyperCelTM Mixed-Mode Chromatography Sor-
bent (Pall International) and affinity chromatography using a
HiTrapTM Protein G HP column (GE Healthcare), respectively.16 The
MEP HyperCelTM resin was packed into an XK26/20 column (GE
Healthcare) and equilibrated with PBS pH 7.0 (flow rate 5 mL/min).
Supernatants were loaded onto columns, followed by washing with
PBS pH 7.0. Captured rMOv18 IgE was eluted using 25% (v/v) iso-
propanol, 0.1 mol/L sodium chloride, 10 mmol/L phosphate (pH 7.0).
Eluted antibodies were further purified by size exclusion chromatog-
raphy (SEC) (Gilson HPLC, SuperdexTM 200 10/300 GL column, GE
Healthcare) and analysed by SDS-PAGE chromatography. Antibody
purity was calculated by comparing the area under the curve for
individual peaks on the HPLC-SEC chromatogram.
2.3 | Assessments of antibodies in vivo
2.3.1 | Immunocompetent syngeneic WAG rat
model of FRa-expressing lung metastases
Female Wistar Albino Glaxo (WAG/RijCrl) rats (Charles River) were
maintained and handled in accordance with the Institutional Com-
mittees on Animal Welfare of the UK Home Office in compliance
with The Home Office Animals Scientific Procedures Act, 1986.
Rats were injected intravenously with CC531tFR tumour cells and
subsequently treated with rMOv18 antibodies on days 1 and 14
or on days 1, 7, 14 and 21. Animals were humanely euthanized,
and lung tumour burden was determined by i) mean number of
surface-visible metastases/cm2 and ii) % tumour occupancy (total
white surface area [mm2]/total lung (black + white) surface area
[mm2]).11
2.3.2 | Clinical observations and measurements
Animals were examined twice daily for clinical signs of toxicity or
changes in behaviour and appearance. On dosing days, animals
were examined after dose completion and approximately 1 and
4 hours thereafter. Animals were weighed at the start of treatment
and weekly thereafter. General toxicities were evaluated according
to the Federation of European Laboratory Animal Science Associa-
tion (FELASA) working group report on pain and distress in labora-
tory rodents17 (Table S1A). Signs of anaphylaxis were evaluated
using a previously described anaphylactic scoring system18
(Table S1B).
2.3.3 | Clinical pathology
Blood samples were drawn into EDTA and lithium heparin collec-
tion tubes and analysed for haemoglobin concentration, total white
blood cell count, neutrophil count, and creatinine, alanine
aminotransferase and aspartate aminotransferase concentrations
(haematological parameters: ADVIA 120 haematology analyser; bio-
chemistry parameters: Roche Modular Evo (P800) clinical chemistry
analyser). Full necropsies were performed at day 30 following
tumour challenge. Tissues were preserved in neutral buffered
formaldehyde before processing for histological evaluation.
2.4 | Histological evaluations
Rat tissues (thymus, injection site (tail), spleen, lymph nodes, liver,
kidney, lungs, colon and brain) were submerged in neutral buffered
formaldehyde, embedded in paraffin wax, cut at a nominal thickness
of 4-5 lm, stained with haematoxylin and eosin and analysed on a
Zeiss Axiophot microscope (910, 920 magnification lenses, Carl
Zeiss) and NIS Elements imaging software (Nikon).
2.5 | Statistical methods
Parametrically distributed data were compared with an unpaired
two-tailed Student’s t test. Nonparametric data were compared using
the Mann-Whitney U test. All statistical analyses were performed
using GraphPadTM Prism software (version 5.03, GraphPadTM). P val-
ues were represented as follows: *P < .05, **P < .01, ***P < .001,
****P < .0001. Error bars represent SD and SEM in in vitro figures,
and SEM in in vivo figures and histological analyses. All results repre-
sent at least 2 independent experiments.
3 | RESULTS
3.1 | Generation and receptor-binding
characteristics of rat MOv18 IgE and IgG2b
We generated anti-human FRa mouse/rat chimeric (mouse variable/
rat constant domains) rMOv18 IgE and IgG2b, surrogates of the orig-
inal mouse/human chimeric hMOv18 IgE and IgG1, respectively. Rat
IgG2b isotype was chosen as equivalent to mouse IgG2a/b and
human IgG1, based on complement activation and antibody-depen-
dent cell-mediated cytotoxicity (ADCC) functions (Figure 1A).19 Vari-
able region DNA sequences for the MOv18 epitope on human FRa
were combined with rat immunoglobulin constant region DNA
sequences. The complete heavy and light chains of each rMOv18
IgE and IgG2b antibody (Figure 1A) were synthesized using GeneArt
Gene Synthesis. Antibody chains were cloned within a dual antibody
expression cassette into a single mammalian expression vector (pVI-
TRO1), by employing an adapted and optimized Polymerase Incom-
plete Primer Extension (PIPE) cloning method that allowed seamless
assembly of multiple DNA fragments.15 The pVITRO-Rat MOv18 IgE
and pVITRO-Rat MOv18 IgG2b vectors (Figure 1B) contained a
hygromycin B resistance gene, enabling antibiotic selection of trans-
fected FreeStyleTM 293-F cells. Semistable cell lines were generated
for large-scale antibody production.
As no universal purification method exists for rat IgE,20 we
designed a strategy using a mixed-mode chromatography resin,
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MEP HyperCelTM, principally operating by hydrophobic charge
induction chromatography (HCIC). The functional ligand, 4-mer-
capto-ethyl-pyridine (MEP), is immunoglobulin-selective and binds a
broad range of immunoglobulin isotypes.16,21 Adsorbed rMOv18
IgE was eluted using a 25% isopropanol elution buffer, and SDS-
PAGE revealed strong bands at the expected molecular weight
(200 kDa for rat IgE)22 (Figure 1C). Following HPLC purification,
human and rat MOv18 IgE (180 and 260 kDa) and MOv18 IgG
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(160 kDa) appeared as single bands,22 corresponding to expected
antibody molecular weights (Figure 1D). HPLC-SEC elution profiles
confirmed the generation of monomeric antibodies of purity >85%
(Figure 1E).
Purified rMOv18 IgE bound to rat FceRI(abc2)-expressing rat
RBL-2H3 mast cells and to primary rat peripheral blood monocytes
(CD172 + ) expressing FceRI(ac2). The rMOv18 IgG2b bound pri-
mary rat monocytes (expressing FccRI) and RBL-2H3 cells (express-
ing low rFccRII/FccRIII levels). Both rat IgE and IgG2b bound to
human FRa-expressing, but not to FRa-negative, tumour cells (Fig-
ure 1F). Consistent with previous findings,7 hMOv18 IgE showed
weak binding, while rat IgE showed significant binding to rat FceRI-
expressing RBL-2H3 cells. Both human and rat MOv18 bound to
human FRa-expressing cancer cells (Figure 1G).
These findings confirm cloning and production of surrogate
rMOv18 antibodies that recognize cognate Fc receptors on rat FcR+
immune cells and target antigen on FRa+ cancer cells.
3.2 | Establishment of a tumour-bearing surrogate
rat model to interrogate IgE functions
Folate receptor a expression is reported to be absent or lowly
expressed in normal tissues,23 and the MOv18 clone may not
cross-react with the rat FRa homologue. We therefore designed a
tumour model in immunocompetent WAG rats with which to study
IgE Fc-mediated antibody functions and safety. The syngeneic
WAG rat adenocarcinoma cell line CC531 was transfected to
express the human FRa (CC531tFR) and formed lung metastases
following systemic challenge (Figure 2A). Flow cytometry confirmed
expression of human FRa by CC531tFR cells (Figure 2B). At chal-
lenge doses between 1.5-7.5 9 106 tumour cells per rat, lung
tumours developed in a dose-dependent manner (number of lung
metastases/cm2) (Figure 2C), and 4.0 9 106 CC531tFR tumour cells
per rat produced satisfactory, but not excessive, development of
lung metastases. We administered antibodies at 2 doses (every
14 days) and confirmed significantly reduced lung metastases
growth with 10 mg/kg rMOv18 IgE compared with rMOv18 IgG2b
or PBS (Figure 2D-E).
We thus confirmed the establishment of a tumour-bearing surro-
gate rat model, in which we demonstrated restriction of syngeneic
tumour growth by rat IgE and IgG2b antibodies, and showed
enhanced efficacy of rMOv18 IgE compared with IgG2b.
3.3 | Safety of rat MOv18 IgE and IgG2b in vivo
We interrogated the rat model with respect to safety using scoring
criteria previously described to evaluate general toxicities in rodents
(Table S1A) and in vivo anaphylactic responses (Table S1B).17,18 We
also conducted histopathological evaluations of several organs to
detect tissue damage, especially from immunological infiltration or
tissue remodelling.
Safety evaluations of rMOv18 IgE were conducted at weekly
doses of 5, 10 and 50 mg/kg and compared with rMOv18 IgG2b
and PBS. Buffer alone-treated rats demonstrated a single toxicity
of subdued but responsive behaviour (69%, mild score; Table S2).
Of the possible general and anaphylactic toxicities, only 3 cate-
gories were observed in rats treated with rMOv18 IgE or IgG2b.
These were as follows: subdued but responsive behaviour; pilo-
erection; and hunching. All toxicities were scored as mild only,
occurred immediately upon waking from anaesthetic, and lasted
for 10-15 minutes thereafter. Severity was similar for both IgE-
and IgG2b-treated rats (Table S2, Figure 3A). Additionally, the
number of toxicities experienced by each animal in each treatment
group was similar between the IgE- and IgG-treated groups at each
dose (Figure 3B). None of the rats in any treatment group experi-
enced any symptom that would constitute an anaphylactic
response, according to a published anaphylaxis scoring system
(Table S1B).18
Histopathological evaluations of several tissues were conducted
to determine potential off-target toxicities. No obvious pathological
lesions associated with 5 or 50 mg/kg IgE, or IgG2b administration,
were detected in major physiological systems (spleen, lymph nodes,
liver, kidney, colon, brain) (Figure 3C). IgE administration had no
effect on body weight (Figure 4A), serum blood chemistry or haema-
tological parameters (creatinine, liver transaminases, haemoglobin
and white blood cell counts) compared with PBS treatment
(Figure 4B-E). As we previously reported in sera of patients with
FRa-expressing carcinomas,14 in this model, we found circulating
antibodies recognizing FRa, irrespective of treatment or antibody
dose. We detected antidrug antibodies (ADA) in the serum of one of
F IGURE 1 Rat MOv18 IgE and IgG2b antibody engineering, purification and characterization. A, Schematic representations of the cloned
rat rMOv18 IgE and IgG2b chimeric antibodies with mouse variable domains specific for the human folate receptor a (FRa) and rat constant
domains (light green: human Ce, dark green: rat Ce, dark orange: human Cc, light orange: rat Cc, light grey: human Cj, dark grey: rat CL, purple:
mouse VH, brown: mouse VL). B, The heavy and light chains of each rMOv18 antibody were cloned into a single mammalian expression vector
per antibody (pVITRO1). This resulted in the production of pVITRO-Rat MOv18 IgE and IgG2b. C, Purification of rMOv18 IgE with MEP
HyperCelTM resin and 25% isopropanol elution buffer (MW: molecular weight marker, F1-F8: fractions 1-8). D, E, non-reducing SDS-PAGE (D)
and HPLC-SEC elution profiles (E) of HPLC-purified hMOv18 IgE and IgG1, and rMOv18 IgE and IgG2b demonstrate intact monomeric
antibodies of purities >85%. F, rMOv18 IgE and IgG2b bind to rat primary monocytes, RBL-2H3 rat mast cells, FRa-expressing rat colon
adenocarcinoma CC531tFR cells and human ovarian carcinoma IGROV1 cells, but not to non-FRa-expressing human melanoma A375 cells.
G, hMOv18 IgE shows weak binding, while rMOv18 IgE demonstrates significant binding to rat FceRI-expressing RBL-2H3 cells. Human and
rat MOv18 IgE display similar binding to human FRa-expressing CC531tFR cells [Colour figure can be viewed at wileyonlinelibrary.com]
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ten rats treated with 10 mg/kg and in the serum of one of ten rats
treated with 50 mg/kg IgE (Figure 4F-G).
We concluded that administration of rMOv18 IgE to tumour-bear-
ing rats induced no clinical, histopathological or metabolic signs of a
type I hypersensitivity reaction, even at weekly 50 mg/kg doses.
3.4 | Immune cell infiltration and immune activation
signatures associated with MOv18 IgE in vivo
IgE antitumour efficacy is likely to function by recruitment of host
immunity. We therefore investigated whether inhibition of lung
metastases in IgE-treated rats was associated with immune cell infil-
tration and activation. We measured growth inhibition of lung
metastases with 4 (weekly) doses of rMOv18 IgE between 1, 10 and
50 mg/kg (Figure 5A-C). Histological evaluation of rat lungs showed
dose-dependent reduction in tumour islet density, alongside immune
and stromal cell infiltration appearing progressively greater with
increasing doses of IgE compared with lesions from PBS-treated rats
(Figure 5D).
We generated mRNA expression profiles from tumour-bearing
rat lungs excised from animals treated with PBS or rMOv18 IgE. We
employed Gene Set Enrichment Analysis (GSEA) to identify gene sets
correlated with treatment. This yielded evidence of significant
enrichment of gene expression associated with immune activation in
IgE-treated tumours, compared with enrichment of cell cycle-asso-
ciated pathways with vehicle treatment (Figure 5E). The IgE-
enhanced, activated genes included those associated with IL-12 and
NK cell immune activation pathways (Figure 5F).
F IGURE 2 Establishment of the tumour-bearing surrogate rat model and antibody-mediated tumour growth restricting potencies. A,
Schematic representation of immunocompetent model design: rMOv18 IgE engages native rat FceR-expressing immune effector cells to target
syngeneic rat tumour cells expressing human folate receptor a (FRa). B, FRa expression of CC531tFR cells immediately prior to in vivo tumour
challenge. C, Determination of optimum i.v. CC531tFR tumour challenge. Representative images of Indian ink-stained lungs reveal white
tumour lesions (n = 5). D, Rat MOv18 IgE demonstrates superior tumour growth restriction. Percentage (%) tumour occupancy and number of
metastases/cm2 quantified following two doses (every 14 days) of PBS, or rMOv18 IgE and IgG2b at 10 mg/kg (n = 6). rMOv18 IgE compared
with rMOv18 IgG2b (mean % tumour occupancy: 8.5% vs 20.7%, P = .003; mean number of lung metastases/cm2: 14.7 vs 31.4, P = .0049) or
with PBS (mean % tumour occupancy: 33.3%, P < .0001; mean number of lung metastases/cm2: 45.2, P < .0001). E, Dosing regimen following
tumour challenge was on days 1 and 14 over a 30-day period [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 Rat MOv18 IgE and IgG induce comparable mild toxicities only. A, Percentage of rats in each treatment group experiencing the
3 detected toxicities (piloerection, hunching and reduced activity). B, Percentage of animals within each treatment group to experience 1, 2 or
3 toxicities. C, Histopathological evaluations of tissues 30 days after administration of two doses (every 14 days) of rMOv18 IgE or IgG2b at
5 mg/kg and 50 mg/kg or PBS rats (n = 10 per group). Sections were stained with H&E and observed at brain = 25 9 magnification; colon,
kidney, liver, mesenteric lymph nodes (LN), tail and thymus = 50 9 magnification; spleen = 100 9 magnification [Colour figure can be viewed
at wileyonlinelibrary.com]
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F IGURE 4 Absence of rMOv18 IgE-associated changes in body weight or blood haematological or biochemical parameters. A, Weekly weights of
rats following weekly treatment with rMOv18 IgE at 1 mg/kg (n = 10), 10 mg/kg (n = 10) and 50 mg/kg (n = 10) or PBS (n = 10). B-E, Blood
biochemical and haematological parameters were measured immediately before necropsy on day 30 following 4 weekly doses of rMOv18
IgE at 1 mg/kg (n = 10), 10 mg/kg (n = 10) and 50 mg/kg (n = 10) or PBS (n = 10). Dotted lines indicate normal range values for each
parameter determined in healthy Wistar Albino Glaxo (WAG)/RijCrl.24 F-G, Rat anti-human folate receptor a (FRa) antibodies and rat
antidrug antibodies (ADA) measured in rat serum following weekly treatment with PBS, or rMOv18 IgE at 1 mg/kg, 10 mg/kg and 50 mg/kg
(n = 10 per group) [Colour figure can be viewed at wileyonlinelibrary.com]
F IGURE 5 Rat MOv18 IgE induces immune cell infiltration and immune activating signatures. A, B, Percentage (%) tumour occupancy and
number of metastases/cm2 quantified following four (weekly) doses of PBS, or rMOv18 IgE at 1 mg/kg, 10 mg/kg and 50 mg/kg (n = 10 per
group). C, Representative images of Indian ink-stained lungs from PBS- and rMOv18 IgE-treated rats (n = 10 per group). D, Representative
images of paraffin-embedded lung sections from PBS- and rMOv18 IgE-treated rats stained with H&E (n = 10 per group). Magnification 200x.
Black arrow: glandular tumour islet; white arrow: immune and stromal cells. E, GSEA analyses showing enrichment of immune-associated
signatures (red) in rMOv18 IgE-treated (two doses, 2 weeks apart) tumour-bearing rat lungs and cell cycle-associated signatures (yellow) in
PBS-treated tumour-bearing rat lungs. Other signatures are shown in blue. The y-axis corresponds to the normalized enrichment score (NES).
F, Heat maps showing the differential expression of all genes that constitute the IL-12 and NK cells signature between rMOv18 IgE- and PBS-
treated rat lungs [Colour figure can be viewed at wileyonlinelibrary.com]
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We previously reported that TNFa-expressing mature macro-
phage subsets infiltrated tumour lesions and that elevated levels of
TNFa were detected in lungs of rMOv18 IgE-treated rats compared
with controls.11 Here, we also observed significantly elevated circu-
lating TNFa in IgE-treated compared with PBS-treated rats
(P = .0044) (Figure 6A-B).11 Previously, we found elevated macro-
phage chemoattractant protein-1 (MCP-1) in the lung environment
of IgE-treated animals potentiated by local upregulation of TNFa fol-
lowing IgE cross-linking on tumour-associated macrophages. Here,
we measured detectable serum MCP-1 in IgE-treated rats, but these
were not significantly elevated compared with controls (Figure 6C).
On the other hand, concentrations of the classical “cytokine storm”-
related cytokines IL-6 and IFN-c were undetectable in rat sera from
all groups. Furthermore, concentrations of IL-4, a key cytokine in the
development of allergic inflammation, were undetectable in sera of
IgE-treated and PBS-treated rats (Figure 6D). These data are consis-
tent with more prominent activation of immune cascades locally in
tumours rather than systemically.
Together these findings point to immune cell recruitment, and
activation of immunological pathways and mediators associated with
F IGURE 6 Rat MOv18 IgE triggers TNFa but no evidence of cytokine storm or allergic response. A, Cytokine/chemokine production
measured in rat serum following weekly treatment with PBS, or rMOv18 IgE at 1 mg/kg, 10 mg/kg and 50 mg/kg (n = 10 per group). B-D,
Concentrations of selected analytes in rat sera
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IgE treatment, in the absence of any evidence of overt toxicities, or
of any cytokine profiles that would indicate signs of cytokine storm
or allergic response activation.
4 | DISCUSSION
Identification of an appropriate animal model for studies involving IgE
functions, including cancer immunotherapy, especially with regard to
class-specific immunological efficacy and safety, represents a major hur-
dle in clinical translation of this antibody class. Previous studies have
reported substantial evidence of comparable or superior antitumour
efficacy of hMOv18 IgE compared to its IgG counterpart.8–10,25,26 To
translate this antitumour antibody safely into the clinic, studies con-
ducted in a pharmacologically relevant species are required.
Here, we report findings in support of the in vivo safety of a
tumour-targeting IgE in an immunologically relevant immunocompe-
tent syngeneic rat tumour model, selected because of similarities in
the structure and distribution of FceRI between humans and rats.
We describe upregulation of immune-associated pathways in lung
metastases of IgE-treated rats, associated with antitumour efficacy,
and evidence of elevated serum concentrations of the pro-inflamma-
tory mediator TNFa. By contrast, neither the classical “cytokine
storm”-related cytokine IL-6 nor the key allergic inflammatory cyto-
kine, IL-4, was upregulated. Despite the activation of immunological
pathways associated with IgE treatment, no evidence of systemic or
organ-specific adverse events was detected.
We completed the rat model by generating surrogate rat IgE and
IgG. We present a simple process for cloning heavy and light chains of
any antibody clone into a single mammalian expression vector and
report serum-free production by mammalian cells by scale-up in biore-
actors. These processes are easily adaptable for generating antibodies
of any isotype or specificity. Furthermore, the only currently reported
purification method for monoclonal rat IgE is for a dinitrophenyl-speci-
fic rat IgE (DNP IgE), purified by an affinity column based on antigen
specificity.20 By contrast, our purification process for rat IgE regardless
of antigen specificity using HCIC is also applicable for human IgE
purification. Engineering, cloning and purification of intact, functional
IgE of sufficient purity and yield for in vivo studies reported in the
design of this rat model represents a methodology applicable to the
generation of IgE and IgG antibodies of any specificity and species.
Administration of rMOv18 IgE and IgG2b to tumour-bearing rats
demonstrated only three toxicities, observed with both isotypes.
Accordingly, none of the anaphylaxis-specific toxicities detailed in
previously published criteria18 were detected with any treatment.
Moreover, immunohistochemical toxicity studies on several tissues
from IgE-, IgG2b- and PBS-treated rats revealed no evidence of
pathological lesions, even at weekly 50 mg/kg antibody doses.
Together with our previously published data, these findings support
clinical systemic MOv18 IgE administration.14
We previously reported that human IgE cross-linked on the sur-
face of human monocytes triggered monocyte activation and TNFa
upregulation; furthermore, human IgE antitumour ADCC was
associated with enhanced TNFa. In parallel, we detected TNFa-
expressing macrophage subsets and elevated concentrations of
TNFa in lung metastases of IgE-treated rats.11 Consistent with these,
here IgE treatment enhanced immune cell recruitment in rat lung
tumours, and activation of immunological pathways in tumour-bear-
ing lungs, alongside elevated TNFa in the sera of IgE-treated rats
compared with controls. Although previously we measured elevated
concentrations of MCP-1 alongside enhanced TNFa in rat bron-
choalveolar lavage fluid of IgE-treated animals, here, we did not
observe statistically significant elevation of serum MCP-1 in IgE-trea-
ted rats. This may be because IgE Fc-mediated cross-linking on
tumour-associated macrophages can trigger elevated TNFa, stimulat-
ing local tumour cells to produce MCP-1 in the tumour, and not sys-
temically.11 It is possible that tissue-resident mast cells may also
contribute to IgE-mediated enhanced TNFa expression, and this
requires further investigation.27 These suggest principally local induc-
tion of tumour-associated immune mediator release, immune cell
activation and recruitment by IgE immunotherapy.
The immunocompetent syngeneic tumour model may also pose
certain limitations, including lack of human FRa expression by normal
rat tissues, and unlikely cross-reactivity of rat FRa homologue with
rat MOv18 IgE. Although observed in the circulation of a proportion
of patients with FRa tumours such as ovarian carcinomas and
mesotheliomas,28 we could not detect circulating shed human FRa
(from CC531tFR cells) in rat sera in any of our studies (data not
shown). Furthermore, FceRI-expressing cells in rats remain insuffi-
ciently characterized compared with human cells. Finally, laboratory
rats, similar to mice, are not exposed to environmental allergens and
thus may not display the array of allergen-reactive antibodies poten-
tially found in human patients. In the light of these, other species
such as canine patients who spontaneously develop FRa-expressing
carcinomas may be interrogated. Considerable immunological homol-
ogy between humans and dogs, alongside potential to better recapit-
ulate the complexities of the microenvironment in spontaneously
developed tumours in an immunocompetent species, may further
benefit evaluations of antitumour IgE antibodies.29
In conclusion, we designed and implemented an immunologically
relevant and physiologically representative tumour model which sup-
ports the preclinical safety of an antitumour IgE antibody, MOv18 IgE.
Simultaneously, using this model, we report efficacy of the therapy in
inducing tumour immune cell infiltration and immune pathway activa-
tion in the absence of physiological or immunological evidence of
cytokine storm or allergic reaction. Our findings support the transla-
tion of IgE into the clinic and contribute to the rapidly growing field of
AllergoOncology. Design of this and other immunologically congruent
models may also help delineate IgE class-specific functions in allergic
inflammation, allergen immunotherapy and antiparasitic responses.
ACKNOWLEDGMENTS
We acknowledge the Biomedical Research Centre (BRC) Immune
Monitoring Core and Genomics Core Facility team at Guy’s and St
Thomas’ NHS Foundation Trust for assistance.
JOSEPHS ET AL. | 2339
CONFLICT OF INTERESTS
SNK and JFS are founders and shareholders of IGEM Therapeutics
Ltd. FON is an employee of Sanofi US. All other authors declare no
conflict of interests.
AUTHOR CONTRIBUTIONS
D.H.J. and M.N. designed experiments. D.H.J., M.N., H.J.B., T.D.,
G.M., L.S., P.K., K.M.I., S.C., P.G., N.W., C.L., S.K., C.S., H.L., S.C., M.F.
and N.D. performed the research. D.H.J., M.N., H.J.B., T.D., G.M.,
L.S., P.K., K.M.I., S.C., P.G., N.W., C.L., S.K., C.S., H.L., S.C., M.F.,
N.D., S.N.K. and J.F.S analysed the data. D.H.J., M.N., H.J.B., T.D.,
G.M., F.O.N., P.S.J., H.J.G., P.J.B., S.T., S.N.K. and J.F.S interpreted
the data. D.H.J., H.J.B., T.D., G.M., F.O.N., P.S.J., H.J.G., P.J.B., S.T.,
S.N.K. and J.F.S wrote the manuscript. L.S., P.K., K.M.I., S.C., P.G.,
N.W., C.L., S.K., C.S., H.L., S.C., M.F. and N.D. all generated or pro-
vided key reagents. F.O.N., P.S.J., H.J.G., P.J.B. and S.T. discussed
the data. S.N.K. and J.F.S conceived this study. S.N.K. designed the
study, supervised and coordinated the project.
ORCID
S. N. Karagiannis http://orcid.org/0000-0002-4100-7810
REFERENCES
1. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a
phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N
Engl J Med. 2006;355:1018-1028.
2. European Medicines Agency, Committee for Medicinal Products for
Human Use (CHMP). Guideline on strategies to identify and mitigate
risks for first-in-human and early clinical trials with investigational
medicinal products. 2017.
3. Dekkers G, Bentlage AEH, Stegmann TC, et al. Affinity of human IgG
subclasses to mouse Fc gamma receptors. mAbs. 2017;9:767-773.
4. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiol-
ogy to pathology. Annu Rev Immunol. 1999;17:931-972.
5. Bettler B, Hofstetter H, Rao M, Yokoyama WM, Kilchherr F, Conrad
DH. Molecular structure and expression of the murine lymphocyte
low-affinity receptor for IgE (Fc epsilon RII). Proc Natl Acad Sci USA.
1989;86:7566-7570.
6. Dombrowicz D, Quatannens B, Papin JP, Capron A, Capron M.
Expression of a functional Fc epsilon RI on rat eosinophils and
macrophages. J Immunol. 2000;165:1266-1271.
7. Mallamaci MA, Chizzonite R, Griffin M, et al. Identification of sites
on the human Fc epsilon RI alpha subunit which are involved in
binding human and rat IgE. J Biol Chem. 1993;268:22076-22083.
8. Gould HJ, Mackay GA, Karagiannis SN, et al. Comparison of IgE and IgG
antibody-dependent cytotoxicity in vitro and in a SCID mouse xeno-
graft model of ovarian carcinoma. Eur J Immunol. 1999;29:3527-3537.
9. Karagiannis SN, Wang Q, East N, et al. Activity of human monocytes
in IgE antibody-dependent surveillance and killing of ovarian tumor
cells. Eur J Immunol. 2003;33:1030-1040.
10. Karagiannis SN, Bracher MG, Hunt J, et al. IgE-antibody-dependent
immunotherapy of solid tumors: cytotoxic and phagocytic mecha-
nisms of eradication of ovarian cancer cells. J Immunol.
2007;179:2832-2843.
11. Josephs DH, Bax HJ, Dodev T, et al. Anti-folate receptor-alpha IgE
but not IgG recruits macrophages to attack tumors via TNFalpha/
MCP-1 signaling. Cancer Res. 2017;77:1127-1141.
12. Karagiannis SN, Josephs DH, Bax HJ, Spicer JF. Therapeutic IgE anti-
bodies: harnessing a macrophage-mediated immune surveillance
mechanism against cancer. Cancer Res. 2017;77:2779-2783.
13. Dreskin SC, Goldsmith PK, Strober W, Zech LA, Gallin JI. Metabo-
lism of immunoglobulin E in patients with markedly elevated
serum immunoglobulin E levels. J Clin Investig. 1987;79:1764-
1772.
14. Rudman SM, Josephs DH, Cambrook H, et al. Harnessing engineered
antibodies of the IgE class to combat malignancy: initial assessment
of FcvarepsilonRI-mediated basophil activation by a tumour-specific
IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp
Allergy. 2011;41:1400-1413.
15. Dodev TS, Karagiannis P, Gilbert AE, et al. A tool kit for rapid cloning
and expression of recombinant antibodies. Sci Rep. 2014;4:5885.
16. Schwart W, Judd D, Wysocki M, Guerrier L, Birck-Wilson E,
Boschetti E. Comparison of hydrophobic charge induction chro-
matography with affinity chromatography on protein A for harvest
and purification of antibodies. J Chromatogr A. 2001;908:251-263.
17. FELASA. Pain and distress in laboratory rodents and lagomorphs.
Report of the Federation of European Laboratory Animal Science
Association (FELASA) Working Group on Pain and Distress. Lab
Anim. 1994;28:97-112.
18. Li Z, Gao Y, Wang H, Liu Z. A rat model of Shuang Huang Lian injection-
induced anaphylaxis. Asian Pac J Allergy Immunol. 2010;28:185-191.
19. Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the
effector functions of human immunoglobulins using a matched set
of chimeric antibodies. J Exp Med. 1987;166:1351-1361.
20. Hanashiro K, Nakamura M, Tamaki N, Kosugi T. Production of a
monoclonal dinitrophenyl-specific rat IgE and establishment of an
IgE capture ELISA for estimating the concentration of rat IgE anti-
bodies to dinitrophenyl-Ascaris suum. Int Arch Allergy Immunol.
1996;110:371-379.
21. Boschetti E. Antibody separation by hydrophobic charge induction
chromatography. Trends Biotechnol. 2002;20:333-337.
22. Bazin H, Querinjean P, Beckers A, Heremans JF, Dessy F. Trans-
plantable immunoglobulin-secreting tumours in rats. IV. Sixty-three
IgE-secreting immunocytoma tumours. Immunology. 1974;26:713-
723.
23. Miotti S, Canevari S, Menard S, et al. Characterization of human
ovarian carcinoma-associated antigens defined by novel monoclonal
antibodies with tumor-restricted specificity. Int J Cancer.
1987;39:297-303.
24. Charles River Laboratories. Baseline haematology and clinical chem-
istry values for Charles River Wistar rats as a function of sex and
age. 1998.
25. Karagiannis SN, Bracher MG, Beavil RL, et al. Role of IgE receptors
in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian
tumor cells by human monocytic cells. Cancer Immunol Immunother.
2008;57:247-263.
26. Karagiannis P, Singer J, Hunt J, et al. Characterisation of an engi-
neered trastuzumab IgE antibody and effector cell mechanisms tar-
geting HER2/neu-positive tumour cells. Cancer Immunol Immunother.
2009;58:915-930.
27. Gordon JR, Galli SJ. Mast cells as a source of both preformed and
immunologically inducible TNF-alpha/cachectin. Nature.
1990;346:274-276.
28. Basal E, Eghbali-Fatourechi GZ, Kalli KR, et al. Functional folate
receptor alpha is elevated in the blood of ovarian cancer patients.
PLoS One. 2009;4:e6292.
29. Fazekas-Singer J, Berroteran-Infante N, Rami-Mark C, et al. Develop-
ment of a radiolabeled caninized anti-EGFR antibody for compara-
tive oncology trials. Oncotarget. 2017;8:83128-83141.
2340 | JOSEPHS ET AL.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: Josephs DH, Nakamura M, Bax HJ,
et al. An immunologically relevant rodent model
demonstrates safety of therapy using a tumour-specific IgE.
Allergy. 2018;73:2328–2341. https://doi.org/10.1111/
all.13455
JOSEPHS ET AL. | 2341
